These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 13227010)

  • 21. Arsenic trioxide in treatment of de novo acute basophilic leukemia.
    Zhao YH; Kong DS; Han LN; Hu LH; Zhang Z; Liu JJ; Liu SX; Qin F; Zhou J
    Chin Med J (Engl); 2013 Feb; 126(3):593-4. PubMed ID: 23422134
    [No Abstract]   [Full Text] [Related]  

  • 22. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Powell BL
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
    [No Abstract]   [Full Text] [Related]  

  • 23. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
    Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
    Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second hematological malignancies during arsenic trioxide therapy of B-cell lymphomas.
    Au WY; Tam S; Fong BM; Wan TS; Yip SF; Kwong YL
    Leuk Res; 2009 Jan; 33(1):191-3. PubMed ID: 18495244
    [No Abstract]   [Full Text] [Related]  

  • 27. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
    Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
    [No Abstract]   [Full Text] [Related]  

  • 28. Arsenic trioxide for refractory aplastic anemia.
    Lin Q; Song Y; Fang B
    Ann Hematol; 2013 Mar; 92(3):431-2. PubMed ID: 23064943
    [No Abstract]   [Full Text] [Related]  

  • 29. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Haanen C; Vermes I
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature.
    Lafayette TC; Coser VM; Brûlé AO; Coser PL; Pereira WV
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):229-32. PubMed ID: 20186102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 33. Bilateral oroantral fistulas following devitalization of teeth by arsenic trioxide: a case report.
    Yalçin S; Aybar B; Haznedaroğlu F; Yücel E
    J Endod; 2003 Mar; 29(3):205-7. PubMed ID: 12669882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
    Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
    Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
    Yamamoto Y; Sasaki M; Oshimi K; Sugimoto K
    Acta Haematol; 2009; 122(1):52-3. PubMed ID: 19816009
    [No Abstract]   [Full Text] [Related]  

  • 36. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
    Naithani R; Mahapatra M; Kumar R; Kumar A; Agrawal N
    Ann Hematol; 2007 Feb; 86(2):151-2. PubMed ID: 17072614
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 40. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Tallman MS
    Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.